Biomarin Net Income from 2010 to 2024

BMRN Stock  USD 90.07  0.40  0.44%   
Biomarin Pharmaceutical Net Income yearly trend continues to be very stable with very little volatility. Net Income is likely to grow to about 176 M this year. During the period from 2010 to 2024, Biomarin Pharmaceutical Net Income quarterly data regression pattern had range of 1.5 B and standard deviation of  307,173,593. View All Fundamentals
 
Net Income  
First Reported
1999-03-31
Previous Quarter
40.4 M
Current Value
20.4 M
Quarterly Volatility
99 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin main balance sheet or income statement drivers, such as Depreciation And Amortization of 109.6 M, Interest Expense of 18 M or Selling General Administrative of 246.1 M, as well as many exotic indicators such as Price To Sales Ratio of 7.11, Dividend Yield of 0.0017 or PTB Ratio of 3.99. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.
  
This module can also supplement Biomarin Pharmaceutical's financial leverage analysis and stock options assessment as well as various Biomarin Pharmaceutical Technical models . Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Net Income Growth Pattern

Below is the plot of the Net Income of Biomarin Pharmaceutical over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Biomarin Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Biomarin Pharmaceutical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Biomarin Pharmaceutical's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 167.65 M10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Biomarin Net Income Regression Statistics

Arithmetic Mean(15,715,517)
Coefficient Of Variation(1,955)
Mean Deviation187,405,311
Median(64,080,000)
Standard Deviation307,173,593
Sample Variance94355.6T
Range1.5B
R-Value0.43
Mean Square Error83192.1T
R-Squared0.18
Significance0.11
Slope29,245,371
Total Sum of Squares1320978.6T

Biomarin Net Income History

2024176 M
2023167.6 M
2022141.6 M
2021-64.1 M
2020854 M
2019-23.8 M
2018-77.2 M

Other Fundumenentals of Biomarin Pharmaceutical

Biomarin Pharmaceutical Net Income component correlations

About Biomarin Pharmaceutical Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Biomarin Pharmaceutical income statement, its balance sheet, and the statement of cash flows. Biomarin Pharmaceutical investors use historical funamental indicators, such as Biomarin Pharmaceutical's Net Income, to determine how well the company is positioned to perform in the future. Although Biomarin Pharmaceutical investors may use each financial statement separately, they are all related. The changes in Biomarin Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biomarin Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Biomarin Pharmaceutical Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Biomarin Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income167.6 M176 M
Net Income Applicable To Common Shares162.8 M170.9 M
Net Income From Continuing Ops147 M154.4 M
Net Income Per Share 0.89  0.94 
Net Income Per E B T 0.89  0.93 

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving against Biomarin Stock

  0.77MRSN Mersana Therapeutics Downward RallyPairCorr
  0.73EOLS Evolus Inc Financial Report 14th of May 2024 PairCorr
  0.62INZY Inozyme PharmaInc Financial Report 14th of May 2024 PairCorr
  0.58JSPRW Jasper TherapeuticsPairCorr
  0.53IOVA Iovance Biotherapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Biomarin Stock analysis

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.98
Earnings Share
0.87
Revenue Per Share
12.88
Quarterly Revenue Growth
0.202
Return On Assets
0.0163
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.